Literature DB >> 28784698

Kidney Disease in HIV: Moving beyond HIV-Associated Nephropathy.

Vasantha Jotwani1,2, Mohamed G Atta3, Michelle M Estrella4,2.   

Abstract

In developed countries, remarkable advances in antiretroviral therapy have transformed HIV infection into a chronic condition. As a result, HIV-associated nephropathy, the classic HIV-driven kidney lesion among individuals of African descent, has largely disappeared in these regions. However, HIV-positive blacks continue to have much higher rates of ESRD than HIV-positive whites, which could be attributed to the APOL1 renal risk variants. Additionally, HIV-positive individuals face adverse consequences beyond HIV itself, including traditional risk factors for CKD and nephrotoxic effects of antiretroviral therapy. Concerns for nephrotoxicity also extend to HIV-negative individuals using tenofovir disoproxil fumarate-based pre-exposure prophylaxis for the prevention of HIV infection. Therefore, CKD remains an important comorbid condition in the HIV-positive population and an emerging concern among HIV-negative persons receiving pre-exposure prophylaxis. With the improved longevity of HIV-positive individuals, a kidney transplant has become a viable option for many who have progressed to ESRD. Herein, we review the growing knowledge regarding the APOL1 renal risk variants in the context of HIV infection, antiretroviral therapy-related nephrotoxicity, and developments in kidney transplantation among HIV-positive individuals.
Copyright © 2017 by the American Society of Nephrology.

Entities:  

Keywords:  Apolipoprotein L1; HIV nephropathy; chronic kidney disease

Mesh:

Substances:

Year:  2017        PMID: 28784698      PMCID: PMC5661296          DOI: 10.1681/ASN.2017040468

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  131 in total

1.  From Bench to Bill: How a Transplant Nuance Became 1 of Only 57 Laws Passed in 2013.

Authors:  Brian J Boyarsky; Dorry L Segev
Journal:  Ann Surg       Date:  2016-03       Impact factor: 12.969

2.  Quiz page June 2012: kidney failure in an HIV-positive patient.

Authors:  Silvia Coelho; Samuel Rodrigues Aparício; Rita Manso; Katrina Soto
Journal:  Am J Kidney Dis       Date:  2012-06       Impact factor: 8.860

3.  Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.

Authors:  Pazit Beckerman; Jing Bi-Karchin; Ae Seo Deok Park; Chengxiang Qiu; Patrick D Dummer; Irfana Soomro; Carine M Boustany-Kari; Steven S Pullen; Jeffrey H Miner; Chien-An A Hu; Tibor Rohacs; Kazunori Inoue; Shuta Ishibe; Moin A Saleem; Matthew B Palmer; Ana Maria Cuervo; Jeffrey B Kopp; Katalin Susztak
Journal:  Nat Med       Date:  2017-02-20       Impact factor: 53.440

4.  Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.

Authors:  Sonia Rodríguez-Nóvoa; Pablo Labarga; Antonio D'avolio; Pablo Barreiro; Marta Albalate; Eugenia Vispo; Carmen Solera; Marco Siccardi; Stefano Bonora; Giovanni Di Perri; Vincent Soriano
Journal:  AIDS       Date:  2010-04-24       Impact factor: 4.177

5.  A National Study of Outcomes among HIV-Infected Kidney Transplant Recipients.

Authors:  Jayme E Locke; Shikha Mehta; Rhiannon D Reed; Paul MacLennan; Allan Massie; Anoma Nellore; Christine Durand; Dorry L Segev
Journal:  J Am Soc Nephrol       Date:  2015-03-19       Impact factor: 10.121

6.  Renal transplantation between HIV-positive donors and recipients.

Authors:  Elmi Muller; Delawir Kahn; Marc Mendelson
Journal:  N Engl J Med       Date:  2010-06-17       Impact factor: 91.245

7.  Acute interstitial nephritis associated with atazanavir, a new protease inhibitor.

Authors:  Ursula C Brewster; Mark A Perazella
Journal:  Am J Kidney Dis       Date:  2004-11       Impact factor: 8.860

8.  Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.

Authors:  Kenneth Mugwanya; Jared Baeten; Connie Celum; Deborah Donnell; Thomas Nickolas; Nelly Mugo; Andrea Branch; Jordan Tappero; James Kiarie; Allan Ronald; Michael Yin; Christina Wyatt
Journal:  J Infect Dis       Date:  2016-03-29       Impact factor: 5.226

9.  HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics.

Authors:  Mohamed G Atta; Michelle M Estrella; Michael Kuperman; Matthew C Foy; Derek M Fine; Lorraine C Racusen; Gregory M Lucas; George W Nelson; Andrew C Warner; Cheryl A Winkler; Jeffrey B Kopp
Journal:  Kidney Int       Date:  2012-04-11       Impact factor: 10.612

10.  Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.

Authors:  Anthony Mills; Jose R Arribas; Jaime Andrade-Villanueva; Giovanni DiPerri; Jan Van Lunzen; Ellen Koenig; Richard Elion; Matthias Cavassini; Jose Valdez Madruga; Jason Brunetta; David Shamblaw; Edwin DeJesus; Chloe Orkin; David A Wohl; Indira Brar; Jeffrey L Stephens; Pierre-Marie Girard; Gregory Huhn; Andrew Plummer; Ya-Pei Liu; Andrew K Cheng; Scott McCallister
Journal:  Lancet Infect Dis       Date:  2015-11-02       Impact factor: 25.071

View more
  7 in total

Review 1.  Clinical Pharmacology in HIV Therapy.

Authors:  Mohamed G Atta; Sophie De Seigneux; Gregory M Lucas
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-29       Impact factor: 8.237

Review 2.  Tenofovir nephrotoxicity among Asians living with HIV: review of the literature.

Authors:  Takeshi Nishijima; Hiroyuki Gatanaga; Shinichi Oka
Journal:  Glob Health Med       Date:  2019-12-31

3.  The prevalence and immunological features of anti-glomerular basement membrane antibody in patients with HIV.

Authors:  Wen-Jing Wang; Xiao-Yu Jia; Zhao Cui; Yan Chen; Wei Wang; Jin-Li Lou; Ming-Hui Zhao; Sun Ying
Journal:  BMC Nephrol       Date:  2020-10-08       Impact factor: 2.388

4.  Chronic medical conditions and late effects following non-Hodgkin lymphoma in HIV-uninfected and HIV-infected adolescents and young adults: a population-based study.

Authors:  Renata Abrahão; Qian W Li; Marcio H Malogolowkin; Elysia M Alvarez; Raul C Ribeiro; Ted Wun; Theresa H M Keegan
Journal:  Br J Haematol       Date:  2020-02-20       Impact factor: 8.615

5.  Impact of comorbidity on the risk and cost of hospitalization in HIV-infected patients: real-world data from Abruzzo Region.

Authors:  Simona Cammarota; Anna Citarella; Lamberto Manzoli; Maria Elena Flacco; Giustino Parruti
Journal:  Clinicoecon Outcomes Res       Date:  2018-07-23

Review 6.  Contemporary issues and new challenges in chronic kidney disease amongst people living with HIV.

Authors:  Jack Edward Heron; Corinne Isnard Bagnis; David M Gracey
Journal:  AIDS Res Ther       Date:  2020-03-16       Impact factor: 2.250

7.  Prevalence and risk factors of mild chronic renal failure in HIV-infected patients: influence of female gender and antiretroviral therapy.

Authors:  Marina Pontello Cristelli; Joan Carles Trullàs; Federico Cofán; Naira Rico; Christian Manzardo; Juan Ambrosioni; Josep Lluis Bedini; Asunción Moreno; Fritz Diekmann; Jose Maria Miro
Journal:  Braz J Infect Dis       Date:  2018-05-18       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.